发明授权
- 专利标题： ANTI-CANCER ANTIBODIES WITH REDUCED COMPLEMENT FIXATION
- 专利标题（中）： 具有减少补防抗癌抗体
-
申请号： EP05701002.7申请日： 2005-01-18
-
公开(公告)号： EP1706428B1公开(公告)日： 2009-09-23
- 发明人: GILLIES, Stephen, D.
- 申请人： Merck Patent GmbH
- 申请人地址： Frankfurter Strasse 250 64293 Darmstadt DE
- 专利权人： Merck Patent GmbH
- 当前专利权人： Merck Patent GmbH
- 当前专利权人地址： Frankfurter Strasse 250 64293 Darmstadt DE
- 优先权： US538348P 20040122
- 国际公布： WO2005070967 20050804
- 主分类号： C07K16/30
- IPC分类号： C07K16/30 ; A61P35/00 ; A61K39/395
摘要：
The invention provides modified antibodies directed against GD2 that have diminished complement fixation relative to antibody-dependent, cell-mediated cytotoxicity, which is maintained. The modified antibodies of the invention may be used in the treatment of tumors such as neuroblastoma, glioblastoma, melanoma, small-cell lung carcinoma, B-cell lymphoma, renal carcinoma, retinoblastoma, and other cancers of neuroectodermal origin.
公开/授权文献
- EP1706428A2 ANTI-CANCER ANTIBODIES WITH REDUCED COMPLEMENT FIXATION 公开/授权日：2006-10-04
信息查询
